In Vivo Therapeutics Core (IVT)

Servicecore – Do not remove

In Vivo Therapeutics Core (IVT)

In Vivo Therapeutics Core (IVT)

Core Image

IU Simon Cancer Center

Core Director:

Karen Pollok, Ph D.

Core Manager:

Tony Sinn


The IUSCCC In Vivo Therapeutics Core (IVT) provides investigators with cost-effective and comprehensive services to facilitate the development and testing of novel pharmacological & cellular therapies. The Core will act as a liaison between the Principal Investigator and any other outcome analyses from live-phase studies. The IVT Core also maintains multiple on-site mouse breeding colonies, as well as oversees operation of the cesium irradiator facility.

  • In Vivo Tumor Growth Kinetics – Established lines include: SKOV-3X, & A2780 (Ovarian), A549, H460, & H1975 (Lung), MCF-7, TMD-231, MDA-MB-468, & BT474 (Breast), C32 (Melanoma), H929 & MM1S (Multiple Myeloma), Raji & Granta 519 (NHL), PaCa-2, ASPC-1, Panc-1 (Pancreatic), CHLA-9, CHLA-10, TC-71 (Ewing Sarcoma)

  • PDX model development

  • Pharmacological Investigations: In vitro toxicity testing utilizing primary human hematopoietic cells and clonogenic progenitor assays to test effects of new compounds on normal cellular function.

  • In Vivo Dose Range Finding: Develop a rational dosing regimen for testing efficacy of therapy

  • In Vivo Drug Efficacy/Tumor Xenograft Model: Establish tumors and administer drug regimen

  • Cellular Therapies: Irradiation of mice prior to transplantation, Intravenous injection of hematopoietic stem cells

|2024-02-20T16:42:28-05:00January 17th, 2024|Comments Off on In Vivo Therapeutics Core (IVT)

Get Involved with Indiana CTSI